ELEVATE EXCHANGE AND COLORADO OPTION

ary Updates to Elevate Exchange and Colorado Option Ma (Exchange Bronze HDHP, Exchange Silver Select/Standard, Exchange Gold Select/Standard, Colorado Option Bronze, Colorado Option Bronze,

P&T/Formulary Committee Actions

Formulary Actions Effective: 04/01/2024															
Torridal y Actions Effective: 0-4,02, 202							Formul	fary Status	Utilization M	fanassment	Rationale of Changes				
		Drug Attributes					Markete	place (HIEX)	HI						
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current	Action	Current Status		COMMERCIAL		Optional Benefit Exclusion	Cotional Formulary Exclusion (NEX	Client Communication - MEX
Catagory	brang name	Generic Name	screngen	Dosage Form	Houte	Brano Status	Status	Action	Current Status	Action	COMMERCIAL	Committee Actions	Optional Benefit Exclusion	Optional Formulary Exclusion (HEX	Client Communication - HEX
							4	5=4	PA.	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS.	RIDCIGUAT	0.5 MG	TABLET	ORAL	558						1424			
							4	5+4	PA.	C+PA	Clinical/Safety Strategy	P&T 1024			
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS	RIDCIGUAT	1MG	TABLET	ORAL	558						1024			
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1024			
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS	RIDCIGUAT	1.5 MG	TABLET	ORAL	558	,		74	COPA	Cincal and Joseph	1024			
												PAT			
CARDIOVASCULAR DISEASE - HYPERTENSION	APPARAGE	MINISTRAT	1860	*****	ORAL CONTRACTOR	***	4	5=4	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24			
LANDUNGS, GLAK DODAGE - HTYTE (ERGIUM	AUGMPAS	RECOUNT	780	IABLET	GKAL	208									
							4	544	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS	RIDCIGUAT	2.5 MG	TABLET	ORAL	558									
							4	544	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	ALYQ	TADALAFIL	20 MG	TABLET	ORAL	GENERIC									
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1024			
CARDIOVASCULAR DISEASE - HYPERTENSION	AMBRISENTAN	AMBRISENTAN	5 MG	TABLET	ORAL	GENERIC						1024			
							4	5~4	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	AMBRISENTAN	AMBRISENTAN	10 MG	TABLET	ORAL	GENERIC		544	PA	CIVA	Corocal/savety strategy	1024			
												207			
		BOSENTAN					4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	BOSENTAN	BOSENTAN	125 MG	TABLET	ORAL	GENERIC									-
							4	544	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	BOSENTAN	BOSENTAN	62.5 MG	TABLET	ORAL	GENERIC									
								544	PA.	CHPA	Clinical/Safety Strategy	P&T 1024	Non-Self Administered Drug (NSA)		
CARDIOVASCULAR DISEASE - HYPERTENSION	EPOPROSTENOL SOCIUM	EPOPROSTENOL SOCIUM	1.5 MG	WAL	INTRAVEN.	GENERIC						1024			
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1024	Non-Self Administered Drug (NSA)		
CARDIOVASCULAR DISEASE - HYPERTENSION	EPOPROSTENOL SODIUM	EPOPROSTENOL SODIUM	0.5 MG	WAL	INTRAVEN.	GENERIC	,		**		Cincay annly analogy	1024	HOLL SELL SELLINGER CONTROL CO		
												PAT			
CARDIOVASCULAR DISEASE - HYPERTENSION	EPOPROSTENOL SOCIUM	EPOPROSTENOL SOCIUM (GLYCINE)					4	5=4	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)		
LANDICHAS CHAR DOSAGE - MYTR ISTORUM	DOMOS ISRUE SCHOM	ENDPROPERTY MANUAL PROPERTY AND ADDRESS OF THE PROPERTY ADDRESS OF THE PROPERTY ADDRESS OF THE PROPERTY ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY ADDRES	0.5 MG	VAL.	NIRAYEN.	GENERAL									
							4	544	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)		
CARDIOVASCULAR DISEASE - HYPERTENSION	EPOPEOSTENOL SODIUM	EPOPROSTENOL SODIUM (GLYCINE)	1.5 MG	WAL	INTRAVEN.	GENERIC									
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	LIGREY	SILDENAFIL CITRATE	10 MG/ML	ORAL SUSP	ORAL	558						aqa-			
							4	5=4	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	OPSUMIT	MAGITENTAN	10 MG	TABLET	ORAL	558	-				,,	1024			
								5=4				PAT			
CARDIOVASCULAR DISEASE - HYPERTENSION	CORNETTALLA	THE PROPERTY OF THE PARTY OF TH	0.75.840	*******	ORAH .	***	4	544	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
Southern States - Illes States	Some Hill Description	Introduction condemnate		IOMA I AN											
							4	544	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	ORENITRAM ER	TREPROSTINIL DIOLAMINE	0.125 MG	TABLET ER	ORAL	558									
							4	544	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	ORENITRAM ER	TREPROSTINIL DIOLAMINE	1 MG	TABLET ER	ORAL	558						-			
							4	5=4	PA.	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	ORENITRAM ER	TREPROSTINIL DICLAMINE	2.5 MG	TABLET ER	ORAL	558						1024			
												PAT			
CARDIOVASCULAR DISEASE - HYPERTENSION	ORINITRAM ER	TREPROSTINE DICLAMINE		*******	ORAH .	***	4	5+4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
The state of the s												207			
CARDIOVASCULAR DISEASE - HYPERTENSION	ORENITRAM MONTH 1 TITRATION KT	TREPROSTINIL DIOLAMINE	0.125-0.25	TO ER DSPK	L		4	5+4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
LANDINUWSCULAR DISEASE - HYPERTENSION	UNEN I PAM MUNTH 1 TITRATION KT	THE PHILIS I PRIL DICULATINE	U.1/5-0.25	III CR DSPK	UKAL	338		1	1						†
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	ORENTRAM MONTH 2 TITRATION KT	TREPROSTINE DIOLAMINE	0.125-25	TB ER DSPK	ORAL	558	-	+	1						+
							4	5+4	PA	CHPA	Clinical/Safety Strategy	P&T 1024			
CARDIOVASCULAR DISEASE - HYPERTENSION	ORENTRAM MONTH 3 TITRATION KT	TREPROSTINIL DIOLAMINE	0.125-1 MG	TB ER DSPK	ORAL	558		1				1024			
							1	5=1	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	SILDENAFIL CITRATE	SEDENAFIL CITRATE	20 MG	TABLET	ORAL	GENERIC	L				- many army armity	1024		<u></u>	
			1	1		-	1	1				PAT		-	
CARDIOVASCULAR DISEASE - HYPERTENSION	SILDENAFIL CITRATE	SEDENAFIL CITRATE	10 MG/12.5		INTRAVEN.	GENERIC	1	5-1	PA	CHPA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)		
CONSIDERATION OF THE PERSON OF	MANAGER STRATE	MAKERON IS STEPARE	10 MB/123	NO.	MINAVEN.	unanti.		1							
							1	5+1	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	SILDENAFIL CITRATE	SEDENAFIL CITRATE	10 MG/ML	SUSP RECON	ORAL	GENERIC		1	+ -						
							4	5=4	PA.	C+PA	Clinical/Safety Strategy	P&T 1Q24		FDA Approved Non-Essential	
CARDIOVASCULAR DISEASE - HYPERTENSION	TADUO	TADALAFIL	20 MG/5 ML	ORAL SUSP	ORAL	558						1024			
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	TRACLEER	BOSENTAN	32 MG	TAB SUSP	ORAL	558						1024			
***************************************												pa+			
			1]		4	5+4	PA	C+PA	Clinical/Safety Strategy	P&T 10,24			
CARDIOVASCULAR DISEASE - HYPERTENSION	TREPROSTINIL	TREPROSTINIL SCINUM	1 MG/ML	WAL	NJECTION	GENERIC		1	1						†
							4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	TREPROSTINE.	TREPROSTINE SCINUM	2.5 MG/ML	WAL	NÆCTION	GENERIC	-	+	1						+
							4	5-4	PA.	C+PA	Clinical/Safety Strategy	P&T 1Q24			
CARDIOVASCULAR DISEASE - HYPERTENSION	TREPROSTING.	TREPROSTINE, SCINUM	5 MG/ML	WAL	INJECTION	GENERIC		1				1024			
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1024			
CARDIOVASCULAR DISEASE - HYPERTENSION	TREPROSTINIL	TREPROSTINIL SODIUM	10 MG/ML	WAL	INJECTION	GENERIC		544	· · ·	CHA	Clinical/sanety strategy	1024			

	T	T	1		1									
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO	TREPROSTINIL	1.74MG/2.9	AMPUI-NEB	INHALATION	550	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO DPI	TREPROSTINE	16 MCG	CART INHAL	INHALATION	558	4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO DRI	TREPROSTINIL	32 MCG	CART INHAL	INHALATION	558								
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO DPI	TREPROSTINIL	48 MCG	CART INHAL	INHALATION	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	TWANG DRI	TRESPONTING	64 MCG	CART INHAL	INMALATICN	508	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO DPI	TREPROSTINE	16-32-48	CART INHAL	INHALATION	558	4	54	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO DRI	TREPROSTINIL	16-32 MCG	CART INHAL	INHALATION	558								
CARDIOVASCULAR DISEASE - HYPERTENSION	TY/ASO DRI	TREPROSTINIL	32-48 MCG	CART INHAL	INHALATION	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIONASCI E ARI DEPASE - HOSERTENSION	TWASO INSTITUTIONAL START RIT	TRESPONTING (NEW LIVE (ACCESOR	1 74MG/2 9	AMPULNES	INMALATICN	508	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
							4	S=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO REFILL KIT	TREPROSTINE/NEB ACCESSORES	1.74MG/2.9	AMPUL-NEB	INHALATION	558	4	54	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34		
CARDIOVASCULAR DISEASE - HYPERTENSION	UPTBAVI	SILENPAG	200 MCG	TABLET	ORAL	550								
CARDIOVASCULAR DISEASE - IMPERTENSION	UPTRAV	SILENPAG	400 MCG	TABLET	ORAL	550	4	Sn4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIONASCILLAR DISEASE - HYPERTENSION	UPTRAM	SELENPAG	600 MCG	TABLET	CRAL	558	4	54	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
111 200 00 111 211 211							4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	UPTRAVI	SELEXIPAG	800 MCG	TABLET	ORAL	558	4	544	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34		
CARDIOVASCULAR DISEASE - HYPERTENSION	UPTBAVI	SILENPAG	1000 MCG	TABLET	ORAL	550								
CARDIOVASCULAR DISEASE - HYPERTENSION	UPTEAM	SELEXIPAG	1200 MCG	TABLET	ORAL	550	4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - IMPERTENSION	HIPTEAM	STEPPENG	1400 MCG	TABLET	CRAL	508	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
Commission Manage - Hits Harden	METODA	333.00770	THE MICH	India.	CON.	2.00	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	UPTRAVI	SELEXIPAG	1600 MCG	TABLET	ORAL	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34		
CARDIOVASCULAR DISEASE - HYPERTENSION	UPTRAVI	SELEXIPAG	200-800MCG	TAB DS PK	ORAL	558								
CARDIOVASCULAR DISEASE - HYPERTENSION	UPTRAVI	SELEXIFAG	1800 MCG	WAL	INTRAVEN.	558	4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34	Non-Self Administered Drug (NSA)	
CARDIOVASCULAR DISEASE - HYPERTENSION	WATER OF THE PARTY	ILOPROST TROMETHAMINE	20 MCG/ML	******	Mark STORY		4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
	YAN MAYOR	SANT RACE TO POPULATION	20 W.Carac.	PARTO CIALD	and a second	2.00	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
CARDIOVASCULAR DISEASE - HYPERTENSION	VENTAVIS	ILOPROST TROMETHAMINE	10 MCG/ML	AMPUL-NES	INHALATION	558		543	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34	Non-Self Administered Drug (NSA)	
CARDIOVASCULAR DISEASE - LIPID IRREGULARITY	LEGMO	INCLESIRAN SCORUM	284 MG/1.5	SYRINGE	SUBCUTANE.	558							Non-sen Administrate Grag (KAN)	
DARRETES	инию	SITAGUPTIN	100 MG	TABLET	ORAL	558	3	5-3	Qs. ST	SHQE CHST	Trade Relations Strategy	P&T 1Q24		ST: TRIAL OF JANUARIA, JANUARET, OR JANUARET XII IN THE PAST 120 DAYS
DIABETS	ZTIMO	STAGUETIN	25 MG	TABLET	CRAI	508	3	5-3	QL ST	SHQL CHST	Trade Relations Strategy	P&T 1Q24		ST: TRIAL OF JANUAVIA, JANUAMET, OR JANUAMET OR IN THE PAST 120 DAYS
							3	5-3	Qs. ST	SHQL CHST	Trade Relations Strategy	P&T 1Q24		ST: TRIAL OF JANUAVIA, JANUAMET, OR JANUAMET XR IN THE PAST 120 DAYS
DARRES	ZITUNO	SITAGLIPTIN	50 MG	TABLET	ORAL	558	4	54	PA	C+PA	Trade Relations Strategy	FERC JAN 2024		
ENDOCRINE DISORDER - OTHER	NGZNIA	SOMATROGON-GHLA	24MG/1.2ML	PENINETR	SUBCUTANE.	550								
ENDOCEINE DISORDER - OTHER	NGENIA	SCMATROGON-GHIA	60MG/1.2ML	PEN INJETE	SUBCUTANE.	558	4	5=4	PA	C+PA	Trade Relations Strategy	FBRC JAN 2024		
ENDOCRNE DISORDER - OTHER	SOGROYA	SOMAPACITAN-BECD	10MG/1.5MI	PEN INJCTP	SUBCUTANE	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
					and the second		4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
ENDOCRINE DISORDER - OTHER	SCGRCYA	SOMAPACITAN-RECO	5 MG/1.5ML	PEN INICTR	SUBCUTANE.	550	4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34		
ENDOCRINE DISORDER - OTHER	SOGROYA	SOMAPACITAN-BECO	15MG/15ML	PEN INICTR	SUBCUTANE.	558								
ENDOCEME DISORDER - OTHER	SOGROYA	SOMAPACITAN-RECO	10MG/15ML	PEN INJETE	SUBCUTANE.	550	4	544	PA	C+PA	Trade Relations Strategy	FBRC JAN 2024		
ENDOCRINE DISCRIPE - OTHER	SOCIONA	STRANDACTION SECTO	5 MG/1 5MI	DEN IN ETT	SUBCUTANE	508	4	5-4	PA	C+PA	Trade Relations Strategy	FBRC JAN 2024		
					annually.		4	544	PA	C+PA	Trade Relations Strategy	FBRC JAN 2024		
ENDOCRINE DISORDER - OTHER	SOGROYA	SOMAPACITAN-BECD	15MG/1.5ML	PEN INJCTR	SUBCUTANE.	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
EYE - MISCELLANEOUS	BYOOVIZ	RANIEIZUMAS-NUNA	0.5MG/0.05	WAL	INTRAOCULR	558								
EYE - MISCELLANEOUS	CIMERLI	RANBIZUMAB-EQRN	0.5MG/0.05	WAL	INTRACCULR	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
EYE - MISCELLANDOUS	CIMERLI	RANIBIZIMAB-EORN	0.3MG/0.0%	WAL	INTRACCUIP	558	4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
212 STANKS	AND ADDRESS OF THE PARTY OF THE	Commence of addition					4	544	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
EYE - MISCELLANEOUS	ENEA	AFUBERCEPT	2MG/0.05ML	WAL	INTRACCULR	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
EYE - MISCELLANEOUS	EYLEA	AFUSERCEPT	2MG/0.05ML	SYRINGE	INTRAOCULR	558	4	344	rA.	G-PA	Corrical/safety Strategy	1024	now-serr Administered Drug (NSA)	

EYE - MISCELLANEOUS	LUCENTS	RANDIZUMAB	0.5MG/0.05	WAL	INTRADCULR	558	4	54	PA	C-PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
EYE - MISCELLANEOUS	LUCENTS	RANISIZUMAS	0.3MG/0.05	WAL	INTRADCULR	558	4	5=4	PA	C-PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
							4	37	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
EYE - MISCELLANEOUS	LUCENTE	RANDIZUMAB	0.5MG/0.05	SYRINGE	INTRADCULR	558	4	544	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
EYE - MISCELLANEOUS	LUCENTIS	RANEGZIMAS	0.3MG/0.05	SYRINGE	INTRADCULR	558								
HEMATOLOGICAL DISORDERS	EMPAYELI	PEGCETACOPIAN	1080 MG/20	WAL	SUBCUTANE.	558	4	54	PA	C-PA	Clinical/Safety Strategy	P&T 1Q24		
MEMATOLOGICAL DISORDERS	FAEHALTA	IPTACOPAN HCL	200 MG	CAPSULE	ORAL	558	4	3	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
							4	5=4	PA	С-РА	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
HEMATOLOGICAL DISORDERS	SOLIRIS	ECUUZUMAB	300MG/30ML	WAL	INTRAVEN.	558	4	54	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34	Non-Self Administered Drug (NSA)	
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULUUMAB-CWVZ	100MG/3ML	WAL	NTRAVEN.	558	4	34	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34	Non-Self Administered Drug (NSA)	
HEMATOLOGICAL DISORDERS	ULTOMRIS	RAVURIDIMAS-CWVZ	1100 MG/11	MAL	INTRAVEN.	558							Non-Self Administered Drug (NSA)	
HORMONAL DEFICIENCY	TESTOSTERONE ENANTHATE	TESTOSTERONE ENANTHATE	200 MG/ML	WAL	INTRAMUSC.	GENERIC	1	5=1	PA	C=PA	Clinical/Safety Strategy	P&T 1Q24		
HORMONAL DESCREASEY	WOSTED	IESTOSTEBONE ENANTHATE	S/BAG /n SAN	AUTO INICT	SHICHTANE	508	3	5-3	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
							3	5-3	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
HORMONAL DEFICIENCY	XYQSTED	TESTOSTERONE ENANTHATE	75MG/0.5ML	AUTO INICT	SUBCUTANE.	558	3	5:3	PA	C+PA	Clinical/Safety Strategy	P&T 1Q34		
HORMONAL DEFICIENCY	XYOSTED	TESTOSTERONE ENANTHATE	100 MG/0.5	AUTO INICT	SUBCUTANE.	558								
LOWER GASTROINTESTINAL DISORCEES - OTHER	BYLVAY	TARKWYDO	200 MCG	PEL DSP CP	ORAL	558	4	544	PA	C-PA	Clinical/Safety Strategy	9&T 1Q34		
LOWER GASTROINTESTINAL DISORDERS - OTHER	Drivay	OCCUMBAT	500 MCG	PEL DSP CP	ORAL	558	4	54	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
							4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
LOWER GASTROINTESTINAL DISORCERS - OTHER	BILVAY	ODEVORBAT	400 MCG	CAPSULE	ORAL	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
LOWER GASTROINTESTINAL DISORDERS - OTHER	BYLVAY	ODEVOKBAT	1200 MCG	CAPSULE	ORAL	558	4	54	PA	C+PA	Clinical/Safety Strategy			
LOWER GASTROINTESTINAL DISORDERS - OTHER	DVMARU	MARALINIBAT CHLORIDE	9.5 MG/ML	SOLUTION	ORAL	558						P&T 1Q24		
MISCELLANEOUS AGENTS	NEXNAZYME	AVALGULCOSIDASE ALFA-NGFT	100 MG	WAL	INTRAVEN.	558	4	5=4	PA	C=PA	Clinical/Safety Strategy	P&T 1Q34	Non-Self Administered Drug (NSA)	
NICORIASTIC DISPASE	YTANIN	FRITALLITAMOR	40 MG	CAPSIIIE	CRAL	508	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
							4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
NEOPLASTIC DISEASE	XTANDI	ENGALUTAMOR	40 MG	TABLET	ORAL	558	4	3	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
NEOPLASTIC DISEASE	XTANDI	ENZALUTAMIDE	SO MG	TABLET	ORAL	558								
NEUROLOGICAL DISEASE - MISCELLANEOUS	INGREZZA	VALBENAZINE TOSYLATE	40 MG	CAPSULE	CRAL	558	4	3	PA	C-PA	Clinical/Safety Strategy	P&T 1Q24		
NEUROLOGICAL DISEASE - MISCELLANROUS	INGREZZA	VALBENAZINE TOSYLATE	80 MG	CAPSULE	ORAL	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
							4	5=4	PA	С-РА	Clinical/Safety Strategy	P&T 1Q24		
NEUROLOGICAL DISEASE - MISCELLANEOUS	NG REZZA	VALBENAZINE TOSYLATE	SO MG	CAPSULE	ORAL	558	4	5=4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24		
NEUBOLOGICAL DISEASE - MISCELLANICOUS	INGREZZA INITIATION PACK	VALEENAZINE TOSYLATE	40 MG-80MG	CAP DS PK	GRAL	558	4	34	PA	C+PA				
OTHER DRUGS	LUMIZYME	ALGUICOSEDASE ALFA	SO MS	MAL	INTRAVEN.	558					Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
OTHER CRUGS	LUMIZIME	ALGUICOSIDASE ALFA	SO MG	WAL	NTRAVEN.	558	4	5-4	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
OTHER DRUGS	VABYSMO	FARICIMAR-SVDA	6MG/0.05ML	WAL	INTRAOCULE	558	4	54	PA	C+PA	Clinical/Safety Strategy	P&T 1Q24	Non-Self Administered Drug (NSA)	
							3	5-0	PA	C+PA	Trade Relations Strategy	FBRC JAN 2024	Antiobesity	
WEIGHT REDUCTION	COTMIA .	PVENTERMINE/TOPRAMATE	3.75-23 MG	CPMP 24HR	ORAL	558	3	5-3	PA	C=PA	Trade Relations Strategy	FBRC JAN 2024	Antiobesity	
WEIGHT REDUCTION	OSYMIA	PHENTERMINE/TOPRAMATE	7.5MG-45MG	CPMP 24HR	ORAL	558								
WEIGHT REDUCTION	OSYMIA	PHENTERMINE/TOPRAMATE	15 MG-92MG	CPMP 24HR	ORAL	558	3	5-3	PA	C+PA	Trade Relations Strategy	FBRC JAN 2024	Antiobesity	
WEIGHT REDUCTION	gormia.	PHENTERMINE/TOPRAMATE	11.25-69MG	CPMP 24HR	ORAL	558	3	5+3	PA	C-PA	Trade Relations Strategy	FBRC JAN 2024	Antiobesity	
							3	0+2	PA	C+PA	Trade Relations Strategy	FBRC JAN 2024	Antiobesity	
WEIGHT REDUCTION	ZZPSOUND	TRZEPATIOE	2.5 MG/0.5	PEN INICTR	SUBCUTANE.	558	3	0-2	PA	C-PA	Trade Relations Strategy	FBRC JAN 2024	Antiobesity	
WEIGHT REDUCTION	ZZPSOUND	TIRZEPATIDE	5 MG/0.5ML	PEN INJCTR	SUBCUTANE.	558								
WEIGHT REDUCTION	ZZPSOUND	TRZEPATICE	7.5 MG/0.5	PEN INJETR	SUBCUTANE.	558	3	0+2	PA	C-PA	Trade Relations Strategy	FERC JAN 2024	Antiobesity	
WEIGHT REDUCTION	ZEPSCUND	TIRZEPATICE	10MG/0.5ML	PEN INJETR	SUBCUTANE.	558	3	0-2	PA	C-PA	Trade Relations Strategy	FERC JAN 2024	Antiobesity	
WEIGHT REDUCTION	2799CLIMD	THEFFOATING	12.5MG/0.5	PEN INJETR	SHICKTAY*	558	3	0-2	PA	С-РА	Trade Relations Strategy	FBRC JAN 2024	Antiobesity	
Abblida Mil	and the second s	- Control of the Cont		, and the second			3	0-2	PA	C-PA	Trade Relations Strategy	FERC JAN 2024	Antiobesity	
WEIGHT REDUCTION	ZZPSOUND	TIRZEPATION	15MG/0.5ML	PEN INJETR	SUBCUTANE.	558								

MedImpact Managed Formulary Actions

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.

LEGEND

Note: The drug names listed are for reference purposes and denote action on the chemical entity unless otherwise specified. Where generic and brand products for a chemical entity co-exist, coverage and copayment for each will be a function of plan benefit design.

FORM	ULARY	UTILIZATION MA	NAGEMENT (UM)	OPTIONAL BENEFIT EXCLUSION
Formulary Status	Formulary Actions	UM Definition	UM Actions	Coverage for each category will be a function of plan benefit design. These products may be excluded on client benefits. Formulary and UM decisions only apply for clients who choose to provide coverage for these drug categories.
F = Formulary	C = Change	AGE = Age restriction	A = Add UM	Antiobesity
NF = Non-Formulary	E = Excluded drug from formulary	QL = Quantity Limit	D = Delete UM	Cosmetic Indications
E = Excluded	S = Sustain	ST = Step Therapy	C = Change UM	Dietary Supplements and Non-Drug Products
NC = Not covered		PA = Prior Authorization	E = Excluded drug from formulary	Drugs to Treat Impotency or Sexual Dysfunction
S = Specialty		HST= Hard Step (Step without grandfathering- member must try preferred agents)	S = Sustain UM	Infertility
Non-S = Non-Specialty				Medical Foods: Dietary supplements, Enteral Feeding, Infant formula
				Non-Self Administered Drug (NSA)
				Ostomy Supplies
				Class O = Over the Counter Products
				Class Q = Products that are neither drugs nor devices, such as dietary supplements (including prenatal and other vitamins), medical foods, herbal preparations, and bulk flavorings or colorants
				Diagnostics